In this study, researchers aimed to determine whether the addition of durvalumab to gemcitabine plus cisplatin increases time toxicity.
Investigators conducted a retrospective analysis on the efficacy and safety of first-line bendamustine and rituximab in patients with Waldenström macroglobulinemia.
Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new ...
CHICAGO -- Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the ...
Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, ...
YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...
The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results